Ardsley Advisory Partners LP Aurinia Pharmaceuticals Inc. Transaction History

Ardsley Advisory Partners LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $2.25 Million - $3.27 Million	-225,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $2.24 Million - $3.41 Million	-182,000 Reduced 44.72%	225,000 $2.92 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $355,850 - $441,375	27,500 Added 7.25%	407,000 $5.63 Million
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $5.01 Million - $6.32 Million	379,500 New	379,500 $5.59 Million

208

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.